ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
In the first time the regulator has acted against an active pharmaceutical ingredient cartel, the European Commission has fined five companies for price-fixing for the antispasmodic butylscopolamine. Alkaloids of Australia, Alkaloids Corporation, Boehringer Ingelheim, Linnea, and Transo-Pharm will have to pay a total of $14.2 million. A sixth firm, C2 Pharma, was not fined because it revealed the price-fixing to the commission. All six admitted their involvement and agreed to settle the case. A seventh firm, Alchem, did not settle; the investigation in that case is ongoing.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X